Clinical trials: LAM
Hiv
The Effect on Lipid Profile of Switching to Delstrigo in HIV Positive Patients
This is an open label, randomised, two-arm switch study over 48 weeks in which virally suppressed participants on a stable combined ART regimen will be randomised (1:1) to an immediate switch to 3TC/TDF/DOR (immediate switch arm…
- Trial name
- META-D (NCT05289986)
- Testing
- DELSTRIGO 100Mg-300Mg-300Mg Tablet
- Where
- 2 sites in United Kingdom
- Volunteers
- 19 people
- Sponsor
- Chelsea and Westminster NHS Foundation Trust
HIV Infections
Comparison of Anti-HIV Drug Combinations to Prevent Mother-to-Child Transmission of HIV
Pregnant women infected with HIV who take anti-HIV medications during pregnancy lower the risk of passing HIV to their infants. This study will compare how well two different combinations of anti-HIV medications control HIV in…
- Trial name
- NCT00086359
- Testing
- Abacavir sulfate, lamivudine, and zidovudine, Lamivudine/zidovudine, Lopinavir/ritonavir
- Where
- 8 sites in United States, Puerto Rico
- Volunteers
- 19 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Leiomyomatosis
Official Record of Patients Diagnosed With Lymphangioleiomyomatosis (LAM)
Pulmonary lymphoangioleiomyomatosis (LAM) is a rare destructive lung disease typically affecting women of childbearing age. Currently, there is no effective therapy for the disease and the prognosis is poor.
- Trial name
- NCT00001869
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Leprosy
Leprosy Skin Test Antigens Phase 1
This is a small Phase I trial to evaluate the safety of the use as skin test antigens of the immunologically active proteins from the soluble/cytosol and insoluble cell wall of Mycobacterium leprae.
- Trial name
- NCT01920750
- Testing
- MLCwA, MLSA-LAM, Mock Antigen
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Lymphangioleiomyomatosis
Safety and Durability of Sirolimus for Treatment of LAM
The MIDAS study aims to follow male and female LAM patients who are currently taking, have previously failed or been intolerant of, or may (at some time in the future) take mTOR inhibitors (sirolimus or everolimus) as part of…
- Trial name
- MIDAS (NCT02432560)
- Testing
- Sirolimus, Everolimus
- Where
- 20 sites in United States
- Volunteers
- 600 people
- Sponsor
- University of Cincinnati
HIV Infection
Study to Evaluate Darunavir/Ritonavir + Lamivudine Versus Continuing With Darunavir/Ritonavir + Tenofovir/Emtricitabine or Abacavir/Lamivudine in HIV Infected Subject
This is an open label randomized clinial trial to evaluate the treatment with darunavir/ritonavir (800mg/100mg) plus lamivudine (300 mg) once daily versus continuing with darunavir/ritonavir (800mg/100mg) once daily plus…
- Trial name
- DUAL (NCT02159599)
- Testing
- Darunavir/Ritonavir, Lamivudine, Emtricitabine/tenofovir or abacavir/lamivudine
- Where
- 21 sites in Spain
- Volunteers
- 249 people
- Sponsor
- Fundacion SEIMC-GESIDA
Infection, Human Immunodeficiency Virus I, HIV Infection
New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected Subjects
A 48-week study to investigate the safety and effectiveness of a new compact formulation of two already FDA-approved anti-HIV drugs in subjects who have already been receiving treatment for their HIV infection.
- Trial name
- NCT00044577
- Testing
- abacavir/lamivudine, abacavir, lamivudine
- Where
- 76 sites in United States, Belgium and 7 more
- Volunteers
- 166 people
- Sponsor
- ViiV Healthcare
Chronic Hepatitis B
Safety and Antiviral Study of ACH126, 433 (b-L-Fd4C) in Adults With Lamivudine-resistant Chronic Hepatitis B
The purpose of this study was to determine the safety and antiviral hepatitis B virus (HBV) activity of ACH126, 433 in the treatment of adults with lamivudine-resistant chronic hepatitis B.
- Trial name
- NCT00040144
- Testing
- ACH126, 433
- Where
- 18 sites in United States, Canada and 1 more
- Volunteers
- 85 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
HIV Infections
Effectiveness and Safety of Two Forms of Stavudine in HIV-Infected Patients
The purpose of this study is to compare the safety and effectiveness of 2 forms of stavudine (d4T). One form is taken once a day (extended release) and the other form is taken twice a day (immediate release).
- Trial name
- NCT00005918
- Testing
- Efavirenz, Lamivudine, Stavudine
- Where
- 77 sites in United States, Argentina and 14 more
- Volunteers
- 730 people
- Sponsor
- Bristol-Myers Squibb
Chronic Hepatitis B
A Phase IIIb Study to Compare Entecavir Plus Tenofovir vs. Adefovir Added to Continuing Lamivudine Therapy in Adult Patients With Lamivudine-Resistant Hepatitis B Infection
The purpose of this clinical research study is to find out whether a combination of entecavir (ETV) plus tenofovir (TNF) works better against Hepatitis B virus than adefovir (ADV) added to continuing lamivudine (LVD) therapy in…
- Trial name
- NCT00605384
- Testing
- Entecavir + Tenofovir, Adefovir + continuing Lamivudine
- Where
- 29 sites in United States, Belgium and 4 more
- Volunteers
- 4 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis B, Chronic
Continuing Lamivudine Versus Switching to Entecavir in Patients Who Achieved Undetectable Hepatitis B Virus DNA
This is a randomized, open-labelled, prospective 96-week study comparing the antiviral efficacy and safety of switching to entecavir 0.5mg QD from lamivudine versus maintaining lamivudine 100mg QD treatment in CHB patients…
- Trial name
- NCT00637663
- Testing
- Entecavir, Lamivudine
- Where
- 2 sites in South Korea
- Volunteers
- 72 people
- Sponsor
- Pusan National University Hospital
HBV (Hepatitis B Virus), Hepatitis B
Lamivudine and Adefovir to Treat Chronic Hepatitis B
This study will evaluate the safety and effectiveness of lamivudine plus adefovir versus adefovir alone to treat chronic hepatitis B infection.
- Conditions
- HBV (Hepatitis B Virus), Hepatitis B, Hepatitis
- Trial name
- NCT00023309
- Testing
- Lamivudine and adefovir, Adefovir alone
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Hepatitis B
Compare the Efficacy and Safety of 48-week Treatment With Clevudine 30mg Versus Lamivudine 100mg for CHB Infection
The purpose of this study is to compare the efficacy and safety of 48-week treatment with Clevudine 30 mg qd versus lamivudine 100 mg qd for chronic hepatitis B infection.
- Trial name
- NCT00362635
- Testing
- Clevudine
- Where
- 2 sites in Hong Kong
- Volunteers
- 92 people
- Sponsor
- Bukwang Pharmaceutical
Tuberculosis
Evaluating Next Generation LAM Assays and Molecular Diagnostics (POC and Near POC) for the Diagnosis of TB Among People With Presumptive TB: a Prospective Multicentre Diagnostic Accuracy Study
This prospective multicentre study is planned to evaluate the next generation LAM assays and molecular diagnostics (POC and near POC) among people with presumptive Tuberculosis.
- Trial name
- DriveDx4TB (NCT06019052)
- Volunteers
- 1,890 people
- Sponsor
- Foundation for Innovative New Diagnostics, Switzerland
Lymphangioleiomyomatosis
National Lymphangioleiomyomatosis Registry, France
RE-LAM-CE is a registry of lymphangioleiomyomatosis cases in France. its aim is to determine the incidence and prevalence of lymphangioleiomyomatosis in France, including demographic information and information concerning the…
- Trial name
- RE-LAM-CE (NCT01484236)
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Vincent COTTIN
Lymphangioleiomyomatosis, Pulmonary Hypertension
Pulmonary Hypertension in Lymphangioleiomyomatosis
This is a descriptive study of patients with Lymphangioleiomyomatosis and precapillary pulmonary hypertension.
- Trial name
- LAM-PH (NCT00960895)
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires
HIV Infections
3TC or No 3TC for HIV With 3TC Resistance
The purpose of this study is to compare the effects of continuing or discontinuing 3TC treatment in the presence of HIV virus with 3TC resistance for persons who are on a regimen including least three other anti-HIV drugs.
- Trial name
- NCT00143728
- Testing
- Lamivudine
- Where
- 9 sites in Canada
- Volunteers
- 152 people
- Sponsor
- University of British Columbia
HIV Infections
A Phase II, Stratified, Randomized, Double-Blind, Multi-Center Study of the Safety and Efficacy of Adefovir Dipivoxil (ADF) at Two Dose Levels in Triple Combination Therapies With Protease Inhibitors (PI) and Nucleoside Reverse Transcriptase Inhibitors (RTI) for the Treatment of HIV-Infected Patient
To evaluate the safety and tolerance of the combination of adefovir dipivoxil at two comparative doses and nelfinavir plus saquinavir SGC administered orally (Group 1) vs.
- Trial name
- NCT00002184
- Testing
- Nelfinavir mesylate, Levocarnitine, Adefovir dipivoxil
- Where
- 15 sites in United States, Puerto Rico
- Volunteers
- 120 people
- Sponsor
- Gilead Sciences
Infection, Human Immunodeficiency Virus I, HIV Infection
Induction/Simplification With Atazanavir + Ritonavir + Abacavir/Lamivudine Fixed-Dose Combination In HIV-1 Infection
This study was designed to test the efficacy, safety, tolerability and durability of the antiviral response between atazanavir (ATV) + ritonavir (/r) + abacavir/lamivudine(ABC/3TC) Fixed dose combination (FDC) each administered…
- Trial name
- NCT00440947
- Testing
- Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV) + ritonavir (/r), Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV)
- Where
- 72 sites in United States, Canada and 1 more
- Volunteers
- 515 people
- Sponsor
- ViiV Healthcare
HIV Infection, AIDS
Once Daily 3TC, Efavirenz and ddI for HIV Infection
Poor compliance is thought to be a major cause of treatment failure. The TEddI study is a randomised, multi-centre, open-label study in well-controlled treatment-experienced HIV-infected patients to assess compliance with a…
- Trial name
- NCT00214435
- Testing
- once daily minimum 3-drug regimen of anti-retroviral medications
- Where
- Australia
- Volunteers
- 120 people
- Sponsor
- 407 Doctors